leridistim

a recombinant fusion protein containing 14-125 interleukin-3(14-alanine, 50-aspartic acid) fused to granulocyte colony stimulating factor(17-serine)

Also Known As:

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Coupek, P: 1 article (01/2008)
2.	Hrabcáková, V: 1 article (01/2008)
3.	Klabusay, M: 1 article (01/2008)
4.	Lysák, D: 1 article (01/2008)
5.	Mayer, J: 1 article (01/2008)
6.	Navrátil, M: 1 article (01/2008)
7.	Cantin, Jacques: 1 article (10/2002)
8.	Chang, Jose: 1 article (10/2002)
9.	Guevin, Raymond: 1 article (10/2002)
10.	Lindsay, Mary-Ann: 1 article (10/2002)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 10/01/2002 - "Patients with metastatic (44%) or localized breast cancer (56%) were randomized to G-CSF 5 microg/kg subcutaneously (s.c.) daily (n = 135), leridistim 5 microg/kg s.c. " 10/01/2002 - "We conclude that G-CSF is superior to leridistim in the prevention of febrile neutropenia in patients with advanced breast cancer receiving TAC chemotherapy. " 10/01/2002 - "Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial." 10/01/2002 - "This randomized, double-blind, phase III trial compared granulocyte colony-stimulating factor (G-CSF; filgrastim) and leridistim (formerly myelopoietin), a chimeric dual agonist that binds both G-CSF and interleukin-3 receptors, for the prevention of neutropenic complications in patients with breast cancer receiving TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy. "
2.	Febrile Neutropenia 10/01/2002 - "The incidence of febrile neutropenia was 7% in the G-CSF arm, 19% in the daily leridistim arm (P = 0.003 for comparison with G-CSF) and 22% in the alternate-day leridistim arm (P < 0.001 for comparison with G-CSF). " 10/01/2002 - "We conclude that G-CSF is superior to leridistim in the prevention of febrile neutropenia in patients with advanced breast cancer receiving TAC chemotherapy. "
3.	Neutropenia 10/01/2002 - "However, grade 4 neutropenia occurred in 53% of cycles in the G-CSF cohort, 61% of cycles in the daily leridistim group (P = 0.063 for comparison with G-CSF), and 63% of cycles in the alternate-day leridistim group (P = 0.015 for comparison with G-CSF). "
4.	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/01/2008 - "Authors analyzed the effect of two growth factors (leridistim and filgrastim) on the kinetics and phenotype of CD34+ cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation. "

Related Drugs and Biologics

1.	Granulocyte Colony-Stimulating Factor (G-CSF)
2.	Filgrastim (Neupogen)
3.	Interleukin-3 Receptors (Interleukin 3 Receptor)
4.	Doxorubicin (Adriamycin)
5.	Cyclophosphamide (Cytoxan)
6.	Docetaxel (Taxotere)
7.	myelopoietin
8.	Intercellular Signaling Peptides and Proteins (Growth Factors)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)